Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food

Clinical Pharmacology in Drug Development

Volumn 3, Issue 5, 2014, Pages 346-352

  Kakuda, Thomas N ^a   Sekar, Vanitha ^a   Lavreys, Ludo ^b   de Paepe, Els ^b   Stevens, Tanja ^b   Vanstockem, Marc ^b   Vangeneugden, Tony ^b   Hoetelmans, Richard M W ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Bioavailability; Darunavir; HIV protease inhibitor; Pharmacokinetics

Indexed keywords

DARUNAVIR; RITONAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; FOOD INTAKE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE DRUG DOSE; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIET RESTRICTION; FOOD DRUG INTERACTION; METABOLIC CLEARANCE RATE; MIDDLE AGED; NETHERLANDS; ORAL DRUG ADMINISTRATION; POSTPRANDIAL STATE; SOLUTION AND SOLUBILITY; TABLET; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DARUNAVIR; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HEALTHY VOLUNTEERS; HIV PROTEASE INHIBITORS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NETHERLANDS; PHARMACEUTICAL SOLUTIONS; POSTPRANDIAL PERIOD; RITONAVIR; TABLETS; YOUNG ADULT;

EID: 84908568317     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.88     Document Type: Article

References (31)

1. Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naïve HIV-infected individuals. AIDS. 2008; 22:2371-2380.
2. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naïve cohort initiating triple antiretroviral therapy. J Infect Dis. 2005; 191:339-347.
3. Braithwaite RS, Roberts MS, Goetz MB, et al. Do benefits of earlier antiretroviral treatment initiation outweigh harms for individuals at risk for poor adherence? Clin Infect Dis. 2009; 48:822-826.
4. Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially-insured HIV patients in the United States. PLoS ONE. 2012; 7:e31591.
5. Nachega JB, Leisegang R, Bishai D, et al. Association of antiretroviral therapy adherence and health care costs. Ann Intern Med. 2010; 152:18-25.
6. Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Def Syndr. 2009; 50:529-536.
7. DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. February 2013. Available from http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed June 4, 2013.
8. Buchanan AL, Montepiedra G, Sirois PA, et al. Barriers to medication adherence in HIV-infected children and youth based on self- and caregiver report. Pediatrics. 2012; 129:e1244-e1251.
9. Purohit VS. Biopharmaceutic planning for pediatric drug development. AAPS J. 2012; 14:519-522.
10. EACS. European AIDS Clinical Society Guidelines. November 2012. Available from http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EacsGuidelines-v6.1-2edition.pdf. Accessed June 4, 2013.
11. DHHS. Guidelines for the use of antiretroviral agents in pediatric HIV infection. November 2012. Available from http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf. Accessed June 4, 2013.
12. Kasirye P, Kendall L, Adkison KK, et al. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clin Pharmacol Ther. 2012; 91:272-280.
13. Kalász H, Antal I. Drug excipients. Curr Med Chem. 2006; 13:2535-2563.
14. Schöller-Gyüre M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther. 2007; 12:789-796.
15. DAIDS. Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 1.0. December 2004 (clarification August 2009). Available from http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf. Accessed June 4, 2013.
16. Sekar VJ, Spinosa-Guzman S, De Paepe E, et al. Pharmacokinetic interaction trial between darunavir in combination with low dose ritonavir and didanosine. Proceedings of the 4th IAS conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 22-25, 2007. Abstract WEPEB012.
17. Sekar V, Lavreys L, Van de Casteele T, et al. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother. 2010; 54:4440-4444.
18. Sekar V, Tomaka F, Lefebvre E, et al. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone. J Clin Pharmacol. 2011; 51:271-278.
19. Boffito M, Miralles D, Hill A. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100mg once-daily in treatment-naïve and -experienced patients. HIV Clin Trials. 2008; 9:418-427.
20. Back D, Sekar V, Hoetelmans RMW. Darunavir: pharmacokinetics and drug interactions. Antivir Ther. 2008; 13:1-13.
21. Sekar V, Guzman S, Stevens T, DePaepe E, Lefebvre E, Hoetelmans R. Absolute bioavailability of TMC114, administered in the absence and presence of low-dose ritonavir. Proceedings of the 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal, April 20-22, 2006. Abstract P86.
22. Fernandez E, Perez R, Hernandez A, Tejada P, Arteta M, Ramos JT. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics. 2011; 3:53-72.
23. Blanche S, Bologna R, Cahn R, et al. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children, adolescents. AIDS. 2009; 23:2005-2013.
24. Violari A, Bologna R, Kimutai R, et al. ARIEL: 24-week safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to <6 years. Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, February 27-March 2, 2011. Abstract 713.
25. Giaquinto C, Flynn P, Blanche S, et al. Darunavir/ritonavir once daily in treatment-naïve adolescents: 48 week efficacy, safety, tolerability and pharmacokinetic results of the DIONE study. Proceedings of the XIX International AIDS Conference, Washington, DC, USA, July 22-27, 2012. Abstract P_MOPE037.
26. Kakuda KN, Brochot A, van de Casteele R, Opsomer M, Tomaka F. Establishing darunavir dosing recommendations in treatment-naïve and treatment-experienced pediatric patients. Proceedings of the 14th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, The Netherlands, April 22-24, 2013. Abstract O_13.
27. Sekar V, Kestens D, Spinosa-Guzman S, et al. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol. 2007; 47:479-484.
28. Vermeir M, Lachau-Durand S, Mannens G, et al. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab Dispos. 2009; 37:809-820.
29. Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. HIV Med. 2013; 14:49-59.
30. Cahn P, Fourie J, Grinzstein B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011; 25:929-939.
31. Bánhegyi D, Katlama C, da Cunha CA, et al. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN. Curr HIV Res. 2012; 10:171-181.